Replies to post #337795 on Innovation Pharmaceuticals Inc (IPIX)

[rule_rationale]

Study it. I've been studying it since 2011, there have been some struggles, but there have been some moments of brilliance! The acquisition of Brilacidin changed this company. I believe it will provided a standalone defining platform, but also the basis of financial security to enable the development of Kevetrin, the p53 Guardian Angel Genome enabling small molecule, that first made IPIX (then Cellceutix CTIX) such a potential pharmaceutical powerhouse.

Merry Christmas and Happy Holidays to all you fellow investors, 2021 is looking pretty darn great!

[loanranger]

"But I haven't studied this company enough yet to have an opinion on resource allocation or the strengths of the European subsidiary."

I think that even you might have trouble forming an opinion on the IPIX sub. Here's all that anyone knows about it, from the 10K:
"On February 15, 2019, the Company formed IPIX Pharma Limited (“IPIX Pharma”), a wholly-owned subsidiary incorporated under the Companies Act 2014 of Ireland. IPIX Pharma is a Private Company Limited by Shares. The subsidiary will serve as a key hub for strategic collaboration with European companies and medical communities in addition to providing cost-saving efficiencies and flexibility with respect to developing Brilacidin under European Medicines Agency standards."

The IPIX Pharma Limited Annual Report was due in February and hasn't been filed.
I had wondered whether Ireland might be the location of the promised overseas B-Covid trial. Wonder if they need to be current in their filings with the Companies Registration Office in Ireland to do that? Or do they need to document the departure of one of the Subs two officers?


But your quick study skills will help you here. After all, you are in the same spot of your history here....day two...that allowed you to provide your estimate of the trajectory of another pre-revenue small cap.

I'm looking for $125 per share.

I think that's a little cheap, too. It assumes FY10 earnings of $42m, divided up into 5m shares ($8.40 EPS), with a PE of only 15.

You know the one.
IPIX doesn't have the problems that that one turned out to have. What are you looking for here?